Fosun International's 2025 Results Show Resilience and Strategic Focus for Future Growth Fosun International's 2025 results presentation revealed impressive revenue figures and a commitment to strategic growth amid market challenges.

Fosun International's 2025 Results Show Resilience and Strategic Focus for Future Growth #China #Shanghai #Fosun_International #Guo_Guangchang #Fosun_Pharma

Fosun International Reports Impressive 2025 Revenues with a Focus on Sustainable Growth Fosun International announces 2025 revenue of RMB173.43 billion, with 54.7% from overseas markets and plans for future profit growth.

Fosun International Reports Impressive 2025 Revenues with a Focus on Sustainable Growth #China #Hong_Kong #Fosun_International #financial_report #Fosun_Pharma

Fosun Pharma Reports 2025 Annual Results Highlighting Innovation and Global Expansion Fosun Pharma has announced its impressive 2025 annual results, driven by innovation and a strong global presence, showcasing substantial growth.

Fosun Pharma Reports 2025 Annual Results Highlighting Innovation and Global Expansion #China #Shanghai #Fosun_Pharma #Innovative_Drugs #Annual_Results

Sisram Medical and Sinmait Technology: A New Manufacturing Hub in China Sisram Medical collaborates with Sinmait Technology to create a cutting-edge innovation hub in China, enhancing localization and expanding its reach in medical aesthetics.

Sisram Medical and Sinmait Technology: A New Manufacturing Hub in China #China #Beijing #Fosun_Pharma #Sisram_Medical #Sinmait_Technology

Fosun Pharma Reports Significant Financial Growth in Q3 2025 Fosun Pharma's Q3 2025 results showcase impressive financial growth, with revenues exceeding RMB29 billion and innovative drug sales rising sharply.

Fosun Pharma Reports Significant Financial Growth in Q3 2025 #Shanghai #None #financial_results #Fosun_Pharma #Innovative_Drugs

Fosun Pharma Reports Impressive Interim Results for 2025, Showcasing Innovation and Global Expansion Fosun Pharma has exhibited strong interim results for 2025, marked by innovation growth, substantial revenue, and efficient asset management.

Fosun Pharma Reports Impressive Interim Results for 2025, Showcasing Innovation and Global Expansion #China #Shanghai #Healthcare_Innovation #Fosun_Pharma #Innovative_Drugs

Fosun Pharma's XH-S004 Innovative Drug Secures Global Licensing Deal Worth $645 Million Fosun Pharma's subsidiary has entered a licensing agreement for its innovative drug XH-S004, potentially yielding $645 million through development and sales milestones.

Fosun Pharma's XH-S004 Innovative Drug Secures Global Licensing Deal Worth $645 Million #Shanghai #Fosun_Pharma #XH-S004 #Expedition_Therapeutics

Teva and Fosun Pharma Forge Alliance for Next-Gen Cancer Treatment Development Teva Pharmaceutical and Fosun Pharma have teamed up to expedite the development of TEV-56278, a novel anti-PD1-IL2 therapy aimed at improving cancer treatments.

Teva and Fosun Pharma Forge Alliance for Next-Gen Cancer Treatment Development #Israel #Tel_Aviv #Fosun_Pharma #Teva_Pharma #TEV-56278

Fosun International Reports Stable Operational Fundamentals in 2024 Annual Results Fosun International's annual results for 2024 reveal stable revenue, profit metrics, and strategic advancements in a fluctuating global economy.

Fosun International Reports Stable Operational Fundamentals in 2024 Annual Results #China #Hong_Kong #Fosun_International #Fosun_Pharma #Yuyuan

Fosun Pharma's 2024 Annual Results Show Strong Financial Performance and Innovation Growth Fosun Pharma reveals impressive 2024 annual results, showcasing rapid cash flow growth and a focus on innovative drug development strategies.

Fosun Pharma's 2024 Annual Results Show Strong Financial Performance and Innovation Growth #China #Shanghai #Fosun_Pharma #Han_Si_Zhuang #Innovative_Drugs

Raziel Therapeutics and Fosun Pharma Launch Phase 3 Trial for Innovative Fat Reduction Treatment in China Raziel Therapeutics and Fosun Pharma have begun a Phase 3 trial for RZL-012, a drug targeting submental fat reduction, with a launch expected in 2027.

Raziel Therapeutics and Fosun Pharma Launch Phase 3 Trial for Innovative Fat Reduction Treatment in China #China #Tianjin #Fosun_Pharma #RZL-012 #Raziel_Therapeutics

Fosun Pharma's Tenapanor Hydrochloride Tablets Receives NMPA Approval for Dialysis Patients Fosun Pharma has received NMPA approval for Tenapanor Hydrochloride Tablets, an innovative treatment for dialysis patients with hyperphosphatemia in China.

Fosun Pharma's Tenapanor Hydrochloride Tablets Receives NMPA Approval for Dialysis Patients #China #Shanghai #NMPA #Fosun_Pharma #Tenapanor